Systematic Review Evaluates Preclinical Evidence of Senotherapeutics in Musculoskeletal Disorders

A systematic review of 26 preclinical studies reports that senotherapeutics show protective effects against osteoarthritis, osteoporosis, and sarcopenia in murine models, though experimental heterogeneity currently limits clinical translation.

Researchers published a systematic review in Calcified Tissue International evaluating preclinical evidence of senotherapeutics in murine models of age-related musculoskeletal disorders.

The review synthesized findings from 26 experimental studies, including 15 on osteoarthritis, 6 on osteoporosis, and 5 on sarcopenia.

Overall, the analyzed studies reported that senotherapeutics reduced tissue inflammation and improved structural and functional outcomes by modulating pathways associated with cellular senescence.

The authors highlighted that significant heterogeneity in animal models, dosing protocols, and outcome measures currently prevents drawing definitive clinical conclusions.

Age-related musculoskeletal conditions like osteoarthritis, osteoporosis, and sarcopenia represent major causes of morbidity and lack disease-modifying therapies that target underlying aging biology.

The findings provide consolidated preclinical support for cellular senescence as a common pathological driver across multiple distinct skeletal and muscular tissues.

The high heterogeneity noted in therapeutic protocols and model systems underscores the necessity of establishing standardized preclinical benchmarks before these therapies can successfully transition to human clinical trials.

The systematic consolidation of positive preclinical outcomes for senotherapeutics may support investor confidence in the broader senolytics field.

For companies developing treatments for age-related joint diseases, such as Biosplice Therapeutics (active in knee osteoarthritis), the review validates targeting age-associated pathways in musculoskeletal tissues, although Biosplice employs a non-senolytic alternative splicing mechanism.

For developers of senolytics targeting cellular senescence, such as Unity Biotechnology and Deciduous Therapeutics, the review underscores the vast therapeutic potential of the mechanism while highlighting the complex translational hurdles of model and protocol heterogeneity.

Future preclinical trials that utilize standardized dosing regimens and unified outcome measures to enable more direct comparisons.

Development of clinical-stage senotherapeutics targeted specifically at musculoskeletal indications to see if the murine tissue protection translates to human efficacy.